HPV-16/18 E6/E7-Specific T Lymphocytes, Relapsed HPV-Associated Cancers, HESTIA
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
- Status
- WITHDRAWN
- Phase
- PHASE1
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
- Status
- COMPLETED
- Phase
- PHASE2
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself
- Status
- COMPLETED
- Phase
- PHASE2
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2